Perspective Therapeutics has won FDA Fast Track Designation for [212Pb]PSV359, a targeted alpha-particle therapy aimed at fibroblast activation protein (FAP-α), in adults with locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors — a rare sarcoma with no FDA-approved systemic treatment. The 8 October 2026 designation is the Seattle company's third, following earlier Fast Track grants for neuroendocrine tumors and melanoma on the same lead-212 platform.
PSV359's designation in four figures
Financial figures from Perspective's Q2 2026 SEC filing; FAP-α expression figure from independently published tumor-profiling research.
A tumor with no systemic option
Solitary fibrous tumors are rare soft-tissue sarcomas most often treated by complete surgical resection — the accepted standard of care when the tumor is localized. Published literature puts recurrence at 10 to 40 percent even after clean resection, and once a tumor is locally advanced, unresectable or metastatic, there is no FDA- or EMA-approved systemic therapy and no consensus treatment guideline. Conventional chemotherapy performs poorly; the best published prospective data for an off-label option, the antiangiogenic pazopanib, showed a 58% partial response rate that did not hold up durably.
That gap is what makes fibroblast activation protein a credible target here. A tumor-profiling study from the German Cancer Consortium's MASTER program found solitary fibrous tumors had the highest median FAP-α mRNA expression among 126 tumor types analyzed, with protein expression independently confirmed in roughly three-quarters of a separate patient cohort — a biological rationale for aiming a targeted therapy at FAP-α specifically, rather than at the tumor type itself.
Radioligand therapy's climb through 2030
$2.6B → $4.8B
Global radioligand therapeutics market, 2025 to 2030, as forecast by BCC Research; a narrower targeted-alpha-therapy segment is forecast separately.
Sources: BCC Research, Radioligand Therapeutics in Cancer Treatment: Global Markets
Regulatory News outlook
We expect targeted alpha therapies specifically, a narrower and faster-growing slice of the radioligand category, to outpace the broader market's growth as more alpha-emitting programs like PSV359 reach designations and later-stage trials over the rest of the decade.
How we got here: BCC Research's $2.6 billion 2025 base for radioligand therapeutics broadly, growing to $4.8 billion by 2030 at a 13.1% CAGR, is the published range we cite; we do not assign PSV359 a specific share of that total, since it remains in Phase 1/2a with no disclosed commercial timeline.
What else treats an advanced solitary fibrous tumor
| Option | Approach | Evidence | Regulatory status |
|---|---|---|---|
| [212Pb]PSV359 (Perspective) | Targeted alpha-particle radiopharmaceutical vs. FAP-α | Phase 1/2a dose-finding; no efficacy data reported yet | FDA Fast Track Designation, Oct 2026 |
| Surgical resection | Complete surgical removal of the tumor | Standard of care for localized disease; 10–40% recurrence even after clean resection | Not applicable (surgical procedure) |
| Pazopanib (off-label) | Oral multi-kinase antiangiogenic | 58% partial response in a prospective Phase 2 trial, not durable | FDA-approved for other cancers; used off-label in SFT |
| 90Y-FAPI-46 (academic programs) | Beta-emitting FAP-targeted radioligand | Small case series (n=3); near-complete metabolic responses reported | Investigational; no FDA designation reported |
From published clinical literature and company disclosures; not a head-to-head trial, and PSV359 has not yet reported its own efficacy data.
Three designations, one isotope
PSV359 is the third program on Perspective's lead-212 platform to earn FDA Fast Track Designation, after [212Pb]VMT-α-NET for SSTR2-positive neuroendocrine tumors and [212Pb]VMT01 for MC1R-positive melanoma. Each pairs the therapeutic 212Pb isotope with a chemically matched imaging isotope, lead-203, so a scan can confirm a patient's tumor expresses the target before treatment begins — the same image-guided selection logic across three different tumor types and three different targets.
What the Fast Track grant does and does not change
Targets FAP, not the tumor type
PSV359 is built against fibroblast activation protein, expressed across many solid tumors; the Fast Track grant covers its use in FAP-positive solitary fibrous tumors specifically, inside a broader basket trial enrolling FAP-positive solid tumors generally.
Image-guided patient selection
A [203Pb]PSV359 scan confirms FAP-α expression before a patient receives the therapeutic 212Pb version — the same theranostic pairing Perspective uses across its NET and melanoma programs.
Faster FDA contact, not faster proof
Fast Track means more frequent FDA interaction and the option of a rolling review; it does not mean efficacy has been shown. PSV359 remains in an open-label, unblinded, dose-finding study.
“[This designation marks] an important step in advancing the broader PSV359 program.” Thijs Spoor, CEO, Perspective Therapeutics — 8 October 2026 announcement
Spoor's comment ties the SFT designation to the wider ambition behind PSV359, which Perspective is evaluating as a monotherapy and, per company disclosures, in combination approaches within the same FAP-positive solid-tumor study. The company has not published response-rate data for PSV359 in any tumor type as of this announcement; the trial's purpose at this stage is dose-finding and safety, not efficacy.
From a 2023 merger to a third designation
Perspective's path to PSV359
- February 2023
Isoray and Viewpoint merge
Isoray, Inc. and Viewpoint Molecular Targeting, Inc. complete a merger; the combined company rebrands as Perspective Therapeutics and moves from ticker ISR to CATX on NYSE American.
- June 2023
First Fast Track Designation
FDA grants Fast Track to [212Pb]VMT-α-NET for SSTR2-positive neuroendocrine tumors, based on preclinical data.
- September 2024
Second Fast Track Designation
FDA grants Fast Track to [212Pb]VMT01 for MC1R-positive metastatic melanoma.
- 2025
PSV359 enters the clinic
NCT06710756 opens as an open-label Phase 1/2a dose-finding study of [212Pb]PSV359 in FAP-positive solid tumors; dose cohorts begin enrolling through the year.
- 8 October 2026
Third Fast Track Designation
FDA grants Fast Track to [212Pb]PSV359 specifically for FAP-positive solitary fibrous tumors.
- 23–27 October 2026
ESMO Congress data
Perspective has an accepted oral presentation on VMT-α-NET data at ESMO Congress 2026 in Madrid.
What a Phase 2 dose still has to answer
A Fast Track Designation is a regulatory process grant, not a readout. What PSV359 still needs to show is ordinary Phase 1/2a work: a tolerated dose, a safety profile clean enough to expand, and eventually a response signal large enough in FAP-positive solitary fibrous tumors to justify a registrational trial in a cancer this rare. Perspective's own disclosed cash position, $236.9 million as of 30 June 2026 with runway guided into late 2027, gives it room to run that work without an immediate financing event — a different starting position than many companies earn their first Fast Track with.
- Trial status: PSV359 remains in an open-label, dose-finding Phase 1/2a study (NCT06710756) enrolling FAP-positive solid tumors broadly, with the Fast Track grant specific to the solitary-fibrous-tumor subset.
- No efficacy data yet: Perspective has not published response-rate or survival data for PSV359 in any tumor type as of this designation.
- Platform context: This is Perspective's third Fast Track Designation on its 212Pb alpha-particle platform, alongside VMT-α-NET (neuroendocrine tumors) and VMT01 (melanoma).
- Cash position: $236.9 million in cash and short-term investments as of 30 June 2026, with runway guided into late 2027.
Sources & further reading
- Perspective Therapeutics, “Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors,” press release, 8 October 2026. perspectivetherapeutics.com
- GlobeNewswire syndication (Manila Times), 8 October 2026. manilatimes.net
- ClinicalTrials.gov, Study Record NCT06710756, Phase 1/2a Study of [212Pb]PSV359. clinicaltrials.gov
- Perspective Therapeutics, Form 10-Q, period ended 30 June 2026. sec.gov
- Perspective Therapeutics, Form 8-K re: merger and name change, February 2023. sec.gov
- BCC Research, “Radioligand Therapeutics in Cancer Treatment: Global Markets.” bccresearch.com
- StockTitan, “Perspective Therapeutics gets FDA Fast Track for PSV359,” 8 October 2026. stocktitan.net
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA grant Perspective Therapeutics?
Fast Track Designation for [212Pb]PSV359 in adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors, announced 8 October 2026. Fast Track speeds up FDA interaction and review; it is not an approval and does not guarantee one.
What does PSV359 target?
Fibroblast activation protein-alpha (FAP-α), a protein expressed in the supporting tissue of many solid tumors and, per published research, unusually highly expressed in solitary fibrous tumors. PSV359 carries the alpha-emitting isotope lead-212 (212Pb) to FAP-α-expressing cells; a chemically matched imaging isotope, lead-203, selects patients first.
Is this Perspective's first Fast Track Designation?
No, its third. The company already holds Fast Track for [212Pb]VMT-α-NET in neuroendocrine tumors and [212Pb]VMT01 in melanoma. PSV359 is being tested in the same Phase 1/2a trial design, broadened here to solitary fibrous tumors.
Is PSV359 approved or available to patients outside a trial?
No. It remains in an open-label Phase 1/2a dose-finding study (NCT06710756) in FAP-positive solid tumors. Fast Track does not change that status; it is a process designation, not a marketing authorization.
